The global endoscopic ultrasound needles market can be segmented based on product, application, end-user, and region. In terms of product, the market can be divided into aspiration needles (EUS-FNA) and biopsy needles (EUS-FNB). The aspiration needles segment is likely to account for a leading share of the global EUS needles market during the forecast period, owing to wide usage of these needles in pulmonology and gastroenterology. Technological developments in EUS biopsy needles are estimated to result in high growth of the biopsy needles segment during the forecast period. Based on application, the endoscopic ultrasound needles market can be segmented into bronchial EUS needles and enteral EUS needles.

Endoscopic ultrasound (EUS) is a minimally invasive procedure that involves visual as well as ultrasonic imaging of the thoracic and abdominal regions. Since its introduction in the 1980s, EUS has gained wide acceptance among surgeons and physicians in the fields of pulmonology and gastroenterology. A conventional endoscope can provide imaging of the inner wall of the gut, while EUS provides ultrasound imaging of the organs beyond the gut wall. The EUS procedure is performed for diagnostic and therapeutic purposes. Selection of the EUS endoscope depends on the application and the organ. EUS-guided needles are used for collection of specimens from organs such as the pancreas, the liver, and the lymph nodes for cytological and histological studies. These specimens are collected for the diagnosis of pancreatic cancer, hepato-billiary diseases, and metastatic cancer. Other methods used to diagnose these diseases are computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound imaging. However, specimens collected by using EUS-guided needles offer cytological and histological studies of the diseased organ.

EUS needles are widely used for collection of specimens from the pancreas, the liver, and the lymph nodes for diagnosis of cancer and other chronic diseases. According to the American Cancer Society, around 53,670 cases of pancreatic cancer are estimated to be diagnosed in the U.S. by the end of 2017. According to the World Cancer Research Fund International, pancreatic cancer is the 12th most common type of cancer in the world, with around 338,000 new cancer cases diagnosed across the world in 2012. According to the Center for Disease Control & Prevention, around 3.9 million adults were diagnosed with liver disease in the U.S. in 2016. This high prevalence of cancer and liver diseases is likely to lead to adoption of EUS needles for better diagnosis. Moreover, key players are introducing technically advanced EUS needle devices with features such as better ultrasound visibility and better needle strength. This is estimated to fuel the market for EUS needles in the near future. However, high cost of endoscopic ultrasound systems, requirement for skilled operators and technicians, and high cost of EUS needles are factors likely to restrain the market from 2017 to 2025.

Request for Sample Copy of Report:

Increasing adoption of EUS needles in gastroenterology is likely to fuel the enteral EUS needles segment in the next few years. Based on end-user, the market can be segmented into hospitals, ambulatory surgical centers, and specialty clinics. The ambulatory surgical centers segment is estimated to register the maximum growth rate during the forecast period, owing to increasing number of these centers and rising number of endoscopic ultrasound procedures performed in these centers. Major players operating in the global endoscopic ultrasound needles market are Olympus Corporation, Medtronic, Cook Medical, CONMED Corporation, and Boston Scientific Corporation.